Acute Myeloid Leukemia Drugs Market by Drug Type – Hypomethylating Agents – Vidaza (Azacitidine), Dacogen (Decitabine), Cytarabine-based Chemotherapy Drugs, Others; Pipeline Analysis (Phase III Drugs) – Chemotherapy Drugs, Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine); Kinase Inhibitors (Midostaurin, Quizartinib) and Forecast 2017-2021

Acute Myeloid Leukemia Drugs Market by Drug Type – Hypomethylating Agents – Vidaza (Azacitidine), Dacogen (Decitabine), Cytarabine-based Chemotherapy Drugs, Others; Pipeline Analysis (Phase III Drugs) – Chemotherapy Drugs, Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine); Kinase Inhibitors (Midostaurin, Quizartinib) and Forecast 2017-2021

Acute myeloid leukemia (AML) is a rare and heterogeneous blood cancer with a poor overall prognosis. It affects predominantly older adults with a median age at diagnosis of 66 years. The standard therapy for acute myeloid leukemia has not changed meaningfully for the past four decades. Most patients with newly diagnosed AML are offered the combination of standard-dose cytarabine with an anthracycline (daunorubicin or idarubicin) regimen, whereas those with adverse-risk disease are offered allogeneic stem-cell transplant (SCT) in first remission. The treatment of AML is divided into categories based on their mechanisms of action: cytotoxic agents, small-molecule inhibitors, and targeted therapies. These drug candidates range from cytotoxic chemotherapies, targeted small-molecule inhibitors, and monoclonal antibodies. Currently available hypomethylating agents azacitidine and decitabine are FDA-approved for use in the United States. Tyrosine kinase inhibitors (TKIs) or FLT3 inhibitors, such as midostaurin (Rydapt) were developed as targeted therapies that interferes with aberrant tyrosine kinase activation in malignant cells. There are several promising drug such as chemotherapy drugs, fixed-combination drugs and kinase inhibitor candidates are currently in the pipeline.

The global acute myeloid leukemia drugs market segmentation is based on drug type – hypomethylating agents – Vidaza (azacitidine), Dacogen (decitabine), Cytarabine-based chemotherapy drugs, others; pipeline analysis (phase III drugs) – chemotherapy drugs, Vyxeos (fixed-combination drugs: Daunorubicin and Cytarabine); and kinase inhibitors (Midostaurin, Quizartinib).

The global acute myeloid leukemia drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global acute myeloid leukemia drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global acute myeloid leukemia drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global acute myeloid leukemia drugs market and profiled in this report include Astellas Pharma, Astex Pharmaceuticals, Bayer, Boehringer Ingelheim, Celgene (Agios–Celgene), Cyclacel Pharmaceuticals, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis, Onyx Pharma, Otsuka Pharmaceuticals, Pfizer, Roche, Seattle Genetics, Sunesis Pharmaceuticals, and Synta Pharmaceuticals.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Acute Myeloid Leukemia (AML) Drugs Market

1. Drug Type
1.1. Hypomethylating Agents
1.1.1. Vidaza (Azacitidine)
1.1.2. Dacogen (Decitabine)
1.2. Cytarabine-based Chemotherapy Drugs
1.3. Others

2. Pipeline Analysis (Phase III Drugs)
2.1. Chemotherapy Drugs
2.2. Vyxeos (Fixed-combination Drugs: Daunorubicin and Cytarabine)
2.3. Kinase Inhibitors
2.3.1. Midostaurin
2.3.2. Quizartinib

3. Geography
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC
3.5. Rest of the World

4. Company Profiles
4.1. Astellas Pharma
4.2. Astex Pharmaceuticals
4.3. Bayer
4.4. Boehringer Ingelheim
4.5. Celgene (Agios–Celgene)
4.6. Cyclacel Pharmaceuticals
4.7. Daiichi Sankyo
4.8. Jazz Pharmaceuticals
4.9. Novartis
4.10. Onyx Pharma
4.11. Otsuka Pharmaceuticals
4.12. Pfizer
4.13. Roche
4.14. Seattle Genetics
4.15. Sunesis Pharmaceuticals
4.16. Synta Pharmaceuticals

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

Chinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish